Free Trial
→ 'You'll own nothing and be happy' (it's not a theory anymore) (From Decentralized Masters) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 11.15 +0.15 (+1.36%)
As of 11:26 AM Eastern
Compare

CRTX vs. GWMO, BZT, MET1, CTL, and CLA

Should you buy CRISM Therapeutics stock or one of its competitors? MarketBeat compares CRISM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISM Therapeutics include Great Western Mining (GWMO), Bezant Resources (BZT), Metals One (MET1), CleanTech Lithium (CTL), and Celsius Resources (CLA). These companies are all part of the "other industrial metals & mining" industry.

How does CRISM Therapeutics compare to Great Western Mining?

Great Western Mining (LON:GWMO) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Great Western Mining has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Great Western Mining has higher earnings, but lower revenue than CRISM Therapeutics. Great Western Mining is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Great Western MiningN/AN/AN/A-£0.01N/A
CRISM Therapeutics£25K230.74-£792.20K-£4.40N/A

In the previous week, Great Western Mining had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for Great Western Mining and 0 mentions for CRISM Therapeutics. Great Western Mining's average media sentiment score of 0.34 beat CRISM Therapeutics' score of -1.36 indicating that Great Western Mining is being referred to more favorably in the media.

Company Overall Sentiment
Great Western Mining Neutral
CRISM Therapeutics Negative

Great Western Mining's return on equity of -9.48% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Great Western MiningN/A -9.48% -5.92%
CRISM Therapeutics N/A -109.55%-26.77%

5.8% of Great Western Mining shares are held by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are held by institutional investors. 6.6% of Great Western Mining shares are held by insiders. Comparatively, 77.3% of CRISM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Great Western Mining beats CRISM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Bezant Resources?

CRISM Therapeutics (LON:CRTX) and Bezant Resources (LON:BZT) are both small-cap basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Bezant Resources' average media sentiment score of 0.00 beat CRISM Therapeutics' score of -1.36 indicating that Bezant Resources is being referred to more favorably in the news media.

Company Overall Sentiment
CRISM Therapeutics Negative
Bezant Resources Neutral

3.7% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 1.5% of Bezant Resources shares are owned by institutional investors. 77.3% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Bezant Resources shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bezant Resources' return on equity of 39.72% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -109.55% -26.77%
Bezant Resources N/A 39.72%-41.17%

Bezant Resources has lower revenue, but higher earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Bezant Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£25K230.74-£792.20K-£4.40N/A
Bezant ResourcesN/AN/A-£8.40K£0.018.33

CRISM Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Bezant Resources has a beta of 0.852, meaning that its stock price is 15% less volatile than the broader market.

Summary

Bezant Resources beats CRISM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Metals One?

CRISM Therapeutics (LON:CRTX) and Metals One (LON:MET1) are both small-cap basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

3.7% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Metals One shares are held by institutional investors. 77.3% of CRISM Therapeutics shares are held by insiders. Comparatively, 1.1% of Metals One shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Metals One has lower revenue, but higher earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Metals One, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£25K230.74-£792.20K-£4.40N/A
Metals OneN/AN/A-£375.04K-£4.97N/A

In the previous week, Metals One's average media sentiment score of 0.00 beat CRISM Therapeutics' score of -1.36 indicating that Metals One is being referred to more favorably in the news media.

Company Overall Sentiment
CRISM Therapeutics Negative
Metals One Neutral

Metals One's return on equity of -2.94% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -109.55% -26.77%
Metals One N/A -2.94%-112.94%

Summary

CRISM Therapeutics beats Metals One on 5 of the 9 factors compared between the two stocks.

How does CRISM Therapeutics compare to CleanTech Lithium?

CleanTech Lithium (LON:CTL) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, CleanTech Lithium's average media sentiment score of 0.00 beat CRISM Therapeutics' score of -1.36 indicating that CleanTech Lithium is being referred to more favorably in the media.

Company Overall Sentiment
CleanTech Lithium Neutral
CRISM Therapeutics Negative

CleanTech Lithium currently has a consensus price target of GBX 20, indicating a potential upside of 153.16%. Given CleanTech Lithium's stronger consensus rating and higher possible upside, equities research analysts clearly believe CleanTech Lithium is more favorable than CRISM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CleanTech Lithium
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
CRISM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CleanTech Lithium's return on equity of -43.43% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CleanTech LithiumN/A -43.43% -13.50%
CRISM Therapeutics N/A -109.55%-26.77%

CRISM Therapeutics has higher revenue and earnings than CleanTech Lithium. CRISM Therapeutics is trading at a lower price-to-earnings ratio than CleanTech Lithium, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CleanTech LithiumN/AN/A-£2.19M£0.948.40
CRISM Therapeutics£25K230.74-£792.20K-£4.40N/A

0.1% of CleanTech Lithium shares are owned by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are owned by institutional investors. 5.5% of CleanTech Lithium shares are owned by company insiders. Comparatively, 77.3% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CleanTech Lithium has a beta of -0.79, indicating that its share price is 179% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

CleanTech Lithium beats CRISM Therapeutics on 8 of the 13 factors compared between the two stocks.

How does CRISM Therapeutics compare to Celsius Resources?

CRISM Therapeutics (LON:CRTX) and Celsius Resources (LON:CLA) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Celsius Resources' return on equity of -7.35% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -109.55% -26.77%
Celsius Resources N/A -7.35%-4.41%

CRISM Therapeutics has higher revenue and earnings than Celsius Resources. Celsius Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£25K230.74-£792.20K-£4.40N/A
Celsius Resources£647.0022,996.05-£2.33M-£0.06N/A

3.7% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Celsius Resources shares are owned by institutional investors. 77.3% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 21.5% of Celsius Resources shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CRISM Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Celsius Resources has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

In the previous week, Celsius Resources had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Celsius Resources and 0 mentions for CRISM Therapeutics. Celsius Resources' average media sentiment score of 0.00 beat CRISM Therapeutics' score of -1.36 indicating that Celsius Resources is being referred to more favorably in the news media.

Company Overall Sentiment
CRISM Therapeutics Negative
Celsius Resources Neutral

Summary

Celsius Resources beats CRISM Therapeutics on 7 of the 12 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON Exchange
Market Cap£5.77M£1.67B£4.90B£2.78B
Dividend YieldN/A6.55%4.95%6.12%
P/E Ratio-2.5330.3823.31363.21
Price / Sales230.7459,217.607,042.6387,415.95
Price / CashN/A24.6327.4327.85
Price / Book0.265.859.487.74
Net Income-£792.20K£70.60M£156.62M£5.89B
7 Day Performance1.64%0.71%-0.35%0.21%
1 Month PerformanceN/AN/A19.22%N/A
1 Year Performance-38.78%113.05%68.89%74.70%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 11.15
+1.4%		N/A-39.2%£5.77M£25KN/A4
GWMO
Great Western Mining
N/AGBX 4.60
+10.8%		N/A+166.7%£19.09MN/AN/A9
BZT
Bezant Resources
N/AGBX 0.10
-2.9%		N/A+300.0%£18.67MN/A8.335
MET1
Metals One
N/AGBX 1.37
+1.5%		N/A-94.6%£15.48MN/AN/A3
CTL
CleanTech Lithium
2.4276 of 5 stars		GBX 7.50
-6.3%		GBX 20
+166.7%		+23.1%£15.31MN/A7.9820

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
June 4: The day smart money moves (not June 12)
Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...
Behind the Markets | Sponsoredtc pixel
Washington just moved up the "go broke" date on Social Security
The Congressional Budget Office just moved up Social Security's trust fund depletion date to 2032 - a full yea...
Investors Alley | Sponsoredtc pixel
AI breakthrough hidden inside SpaceX exposed on June 11
On June 11, SpaceX is hosting a major investor event - and growth investor Louis Navellier believes Elon Musk ...
InvestorPlace | Sponsoredtc pixel
Jon Najarian’s Important SpaceX PREDICTION
Most investors are focused on SpaceX's projected June 12 IPO date - but they may be missing the bigger story h...
Banyan Hill Publishing | Sponsoredtc pixel